Ignyta Dumps Two Ex-Teva Oncology Programs
This article was originally published in Scrip
Executive Summary
Ignyta, which last year took over rights to four oncology programs from Teva and gave up a sizeable equity stake in return, is now "deprioritizing" two of the products in addition to one internally derived program.